On the other hand, alterations in the MET gene have been identified as actionable oncogenic alterations [5], and MET gene amplification plays an important role in the growth and survival of non-small cell lung cancer (NSCLC) [6] by enhancing binding to receptor tyrosine kinases (RTKs), which then initiates a series of signal transduction pathways associated with proliferation and metastasis [7]. This evidence concerns the gene MET and non-small cell lung carcinoma.